Abiomed Announces Q1 FY 2016 Revenue of $73.4 Million, Up 50% Over Prior Year
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Piper Jaffray Raises Price Target on Abiomed (ABMD) Following 1Q16
August 5, 2015 10:15 AM EDTPiper Jaffray reiterated a Neutral rating on ABIOMED (NASDAQ: ABMD), and raised the price target to $85.00 (from $71.00), following 1Q16 results. Abiomed reported F1Q16 revenue of $73.4M vs. consensus $66.0M. Management plans to provide a business update including a 5-year plan and pipeline update at its August 11 investor... More
Abiomed (ABMD) Tops Q1 EPS by 12c
August 4, 2015 7:03 AM EDTAbiomed (NASDAQ: ABMD) reported Q1 EPS of $0.20, $0.12 better than the analyst estimate of $0.08. Revenue for the quarter came in at $73.4 million versus the consensus estimate of $66.27 million.
Abiomed sees FY2015 revenue of $300-310 million, versus prior guidance of $285-295 million and the consensus of $292.4... More
